Todd W Miller

16PUBLICATIONS
35CO-AUTHORS
Environmental epidemiologyMolecular targetsTumour immunologyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jul 17, 2026
Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer.

|Apr 01, 2026
Metabolic Response to CDK4/6 Inhibition in ER+ Breast Cancer Creates a Therapeutic Vulnerability in Drug-Tolerant Persister Cells.

Huijuan Yang, Steven Tau, Andrew D McCray

|Nov 24, 2025
Epithelial-Mesenchymal Transition is Associated with Altered Immune Composition and Cytotoxic Function in Triple-Negative Breast Cancer.

Hanxu Lu, Meisam Bagheri, Fred W Kolling

|Aug 08, 2025
Endocrine therapy induces oxidative stress in ER+ breast cancer that sensitizes persister cells to ferroptosis.

Steven Tau, Malone Friedman, Alyssa M Roberts

|Jan 08, 2025
Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy-Tolerant Persister Cells in ER+ Breast Cancer.

Steven Tau, Mary D Chamberlin, Huijuan Yang

|Oct 10, 2024
Endocrine persistence in ER+ breast cancer is accompanied by metabolic vulnerability in oxidative phosphorylation.

Steven Tau, Mary D Chamberlin, Huijuan Yang

Pageof 3

Frequent Collaborators

3 joint publications

Steven Tau

3 joint publications

Eugene Demidenko

3 joint publications

Jonathan D Marotti

3 joint publications

Fred W Kolling